GSK vets the­o­rize that a mi­to­chon­dr­i­al tar­get may un­lock Parkin­son's and ALS treat­ments in new start­up

Can tar­get­ing a mi­to­chon­dr­i­al path­way pre­vi­ous­ly thought to be un­drug­gable crack the code in dev­as­tat­ing neu­rode­gen­er­a­tive dis­eases, such as Parkin­son’s and ALS? For a new …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER